Q BioMed Inc. Updates on Corporate Developments

Q BioMed Inc. (OTCQB:QBIO) provided the following update on recent corporate developments.
According to the company’s press release:

Over the last 3 months we have significantly increased our cash position through several convertible note and securities purchase agreements exceeding $1,000,000. As a result, we have positioned ourselves to execute on the initial commitments under our Mannin Research Inc. license agreement and expect that development to continue on schedule.
Mannin’s leading technology platform, MAN-01, is moving forward as planned with molecule optimization and the asset development program is being finalized.

Mannin’s CEO, Dr. George N. Nikopoulos stated:

We are thrilled to be a part of the program. We see the value in the acceleration process as it relates to our development and commercialization milestones. We thank the Canadian Trade Commissioner Service in Chicago for their support and look forward to a successful program.

Click here to view the full press release.